Literature DB >> 29635240

Heterogeneity in Lung Cancer.

Vitor Manuel Leitão de Sousa1,2,3,4, Lina Carvalho1,2,3,4.   

Abstract

Lung cancer diagnosis is a challenge since it is also one of the most frequently diagnosed cancers. Diagnostic challenges are deeply related to the development of personalized therapy and molecular and precise histological characterizations of lung cancer. When addressing these features, it is very important to acknowledge the issue of tumour heterogeneity, as it imposes several questions. First of all, lung cancer is a very heterogeneous disease, at a cellular and histological level. Cellular and histological heterogeneity are addressed with emphasis on the diagnosis, pre-neoplastic lesions, and cell origin, trying to contribute to a better knowledge of carcinogenesis. Molecular intra-tumour and inter-tumour heterogeneity are also addressed as temporal heterogeneity. Lung cancer heterogeneity has implications in pathogenesis understanding, diagnosis, selection of tissue for molecular diagnosis, as well as therapeutic decision. The understanding of tumour heterogeneity is crucial and we must be aware of the implications and future developments regarding this field.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Genetics; Heterogeneity; Lung cancer; Molecular pathology

Mesh:

Substances:

Year:  2018        PMID: 29635240     DOI: 10.1159/000487440

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  63 in total

Review 1.  Malic enzyme 1 (ME1) in the biology of cancer: it is not just intermediary metabolism.

Authors:  Frank A Simmen; Iad Alhallak; Rosalia C M Simmen
Journal:  J Mol Endocrinol       Date:  2020-11       Impact factor: 5.098

Review 2.  Mechanisms of resistance to chemotherapy in non-small cell lung cancer.

Authors:  Hye-Young Min; Ho-Young Lee
Journal:  Arch Pharm Res       Date:  2021-02-19       Impact factor: 4.946

3.  Diagnostic and prognostic value of CT perfusion parameters in patients with advanced NSCLC after chemotherapy.

Authors:  Guangyao Lin; Yuan Sui; Yiming Li; Wenqi Huang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

4.  High miR-3648 expression and low APC2 expression are associated with shorter survival and tumor progression in NSCLC.

Authors:  Yongquan Dong; Biao Wu; Xiongxiong Wang; Feijie Lu; Qianjun Li; Qiong Zhao
Journal:  Histol Histopathol       Date:  2021-12-20       Impact factor: 2.303

5.  Novel Primary Human Cancer Stem-Like Cell Populations from Non-Small Cell Lung Cancer: Inhibition of Cell Survival by Targeting NF-κB and MYC Signaling.

Authors:  Beatrice A Windmöller; Morris Beshay; Laureen P Helweg; Clara Flottmann; Miriam Beermann; Christine Förster; Ludwig Wilkens; Johannes F W Greiner; Christian Kaltschmidt; Barbara Kaltschmidt
Journal:  Cells       Date:  2021-04-27       Impact factor: 6.600

6.  Phenotypic Plasticity Conferred by the Metastatic Microenvironment of the Brain Strengthens the Intracranial Tumorigenicity of Lung Tumor Cells.

Authors:  Xu-Ge Wei; Ke-Wei Bi; Bo Li
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

7.  The predictive prognostic values of CBFA2T3, STX3, DENR, EGLN1, FUT4, and PCDH7 in lung cancer.

Authors:  Yuhao Chen; Lu Shen; Bairong Chen; Xiao Han; Yunchi Yu; Xiaosa Yuan; Lou Zhong
Journal:  Ann Transl Med       Date:  2021-05

8.  Generation of Non-Small Cell Lung Cancer Patient-Derived Xenografts to Study Intratumor Heterogeneity.

Authors:  Zoi Kanaki; Alexandra Voutsina; Athina Markou; Ioannis S Pateras; Konstantinos Potaris; Margaritis Avgeris; Periklis Makrythanasis; Emmanouil I Athanasiadis; Ioannis Vamvakaris; Eleni Patsea; Konstantinos Vachlas; Evi Lianidou; Vassilis Georgoulias; Athanasios Kotsakis; Apostolos Klinakis
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

9.  Inflammatory Environment Promotes the Adhesion of Tumor Cells to Brain Microvascular Endothelial Cells.

Authors:  Ke Wang; Shuang Dong; Doaa Higazy; Lijing Jin; Qingcui Zou; Haowei Chen; Aakif Inayat; Sheng Hu; Min Cui
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

Review 10.  Recent Advances and Future Perspective of DC-Based Therapy in NSCLC.

Authors:  Iris A E van der Hoorn; Georgina Flórez-Grau; Michel M van den Heuvel; I Jolanda M de Vries; Berber Piet
Journal:  Front Immunol       Date:  2021-06-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.